Form 4: ALX Oncology CEO Jason Lettmann Granted Stock Options
SEC Form 4 Filing
ALX Oncology's CEO, Jason Lettmann, was granted 478,000 stock options, vesting monthly over four years, according to a recent SEC filing.
Summary
- Jason Lettmann, CEO of ALX Oncology Holdings Inc., was granted 478,000 employee stock options.
- The options have an exercise price of $1.65 per share.
- The options vest in 48 equal monthly installments starting on February 21, 2025.
- The options expire on January 20, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The granting of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of 48 months is typical for such grants, aligning with long-term performance goals.
- The exercise price of $1.65 is specific to ALX Oncology's stock and market conditions at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of the earliest transaction, the grant of stock options. |
| 01/22/2025 | Date of execution of the Power of Attorney. |
| 01/23/2025 | Date of signature of the SEC Form 4 filing. |
| 02/21/2025 | Start date for monthly vesting of the stock options. |
| 01/20/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, SEC Form 4, ALX Oncology, Jason Lettmann, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.